Zenas BioPharma (ZBIO) Profit After Tax (2023 - 2026)

Zenas BioPharma's Profit After Tax history runs 4 years deep, the most recent figure standing at -$81.0 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 141.03% year-over-year to -$81.0 million in Q1 2026; TTM through Mar 2026 was -$425.1 million, a 161.14% decrease from a year earlier, with the FY2025 full-year figure at -$377.7 million, down 140.62% from the prior year.
• Profit After Tax rose to -$81.0 million in Q1 2026 per ZBIO's latest filing, from -$240.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at $35.6 million in Q3 2023 and bottomed at -$240.4 million in Q4 2025.
• The 4-year median for Profit After Tax is -$38.6 million (2024), against an average of -$55.0 million.
• Biggest YoY gain for Profit After Tax was 20.86% in 2025; the steepest drop was 356.93% in 2025.
• Year by year, Profit After Tax stood at -$24.6 million in 2023, then sank by 114.22% to -$52.6 million in 2024, then sank by 356.93% to -$240.4 million in 2025, then surged by 66.32% to -$81.0 million in 2026.
• Per Business Quant, the three latest ZBIO Profit After Tax figures stand at -$81.0 million (Q1 2026), -$240.4 million (Q4 2025), and -$51.5 million (Q3 2025).